Skip to Main Content

The World Health Organization and Unitaid called on Roche (RHHBY) to ensure that existing doses of its Actemra medicine, which is being used to treat Covid-19 patients, are equally available to low and middle-income countries in the face of a global shortage.

In a joint statement, the global health agencies praised the drug maker for addressing the shortage by working with contract manufacturers and distributors to manage production and supplies. But the agencies want the company to transfer technology, as well as share know-how and data, to increase the number of qualified manufacturers. The WHO is soliciting interest from other companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment